Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on January 27, 2003

Hypertension. 2003
Published online before print January 27, 2003, doi: 10.1161/01.HYP.0000050963.16405.E6
A more recent version of this article appeared on February 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/2/286    most recent
01.HYP.0000050963.16405.E6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cracowski, J.-L.
Right arrow Articles by Mallion, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cracowski, J.-L.
Right arrow Articles by Mallion, J.-M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
*PROSTAGLANDIN F2ALPHA
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Hypertension - basic studies
Right arrow Clinical Studies
Right arrow Oxidant stress

Submitted on October 1, 2002
Revised on October 18, 2002

Lipid Peroxidation Is Not Increased in Patients With Untreated Mild-to-Moderate Hypertension

Jean-Luc Cracowski*; Jean-Philippe Baguet; Olivier Ormezzano; Janine Bessard; Françoise Stanke-Labesque; Germain Bessard; and Jean-Michel Mallion

From the Pharmacology and Cardiology Departments, Grenoble University Hospital, Grenoble, France.

* To whom correspondence should be addressed. E-mail: Jean-Luc.Cracowski{at}ujf-grenoble.fr.

Abstract--In contrast with the huge amount of experimental data available, only few and somewhat unconvincing clinical studies support the hypothesis that oxidative stress is involved in the early stages of essential hypertension in humans. Isoprostanes are chemically stable lipid peroxidation products of arachidonic acid, the quantification of which provides a novel approach to the assessment of oxidative stress in vivo. The main objective of this study was to quantify the urinary levels of 15-F2t-IsoP in the early stages of essential hypertension, using gas chromatography/mass spectrometry, by comparing 30 patients with never-treated mild-to-moderate hypertension with 30 gender- and age-paired healthy controls. Urinary 15-F2t-IsoP levels were not significantly different in hypertensive patients (69±36 pmol/mmol creatinine) compared with controls (75±34 pmol/mmol creatinine, 95% confidence intervals on differences: -23 to 13). No significant correlation was found between basal urinary 15-F2t-IsoP levels and age, low-density lipoprotein cholesterol, glucose, clinical pulse pressure, carotid intima-media thickness, left ventricular mass index, or aortic pulse wave velocity. In conclusion, this study shows that lipid peroxidation is not increased in never-treated mild-to-moderate hypertension. This suggests that oxidative stress is not implicated in the pathogenesis of human essential hypertension, at least in the early stages.


Key words: hypertension, essential • prostaglandins • lipid peroxidation • oxidative stress • blood pressure monitoring, ambulatory




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. Wang, S. Strandgaard, J. Iversen, and C. S. Wilcox
Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R195 - R200.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Grossman
Does Increased Oxidative Stress Cause Hypertension?
Diabetes Care, February 1, 2008; 31(Supplement_2): S185 - S189.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. L. Edwards, T. Lyon, S. E. Litwin, A. Rabovsky, J. D. Symons, and T. Jalili
Quercetin Reduces Blood Pressure in Hypertensive Subjects
J. Nutr., November 1, 2007; 137(11): 2405 - 2411.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Lee, M. Lee, J.-U. Kim, K. I. Song, Y. S. Choi, and S.-S. Cheong
Carvedilol Reduces Plasma 8-Hydroxy-2'-Deoxyguanosine in Mild to Moderate Hypertension: A Pilot Study
Hypertension, May 1, 2005; 45(5): 986 - 990.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. D. Morrow
Quantification of Isoprostanes as Indices of Oxidant Stress and the Risk of Atherosclerosis in Humans
Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 279 - 286.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. M. Touyz
Reactive Oxygen Species, Vascular Oxidative Stress, and Redox Signaling in Hypertension: What Is the Clinical Significance?
Hypertension, September 1, 2004; 44(3): 248 - 252.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Minuz, P. Patrignani, S. Gaino, F. Seta, M. L. Capone, S. Tacconelli, M. Degan, G. Faccini, A. Fornasiero, G. Talamini, et al.
Determinants of Platelet Activation in Human Essential Hypertension
Hypertension, January 1, 2004; 43(1): 64 - 70.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-L. Cracowski, J.-P. Baguet, P. Minuz, S. Gaino, M. Degan, L. Menapace, R. Tommasoli, G. Mansueto, E. Arosio, C. L. Santonastaso, et al.
Isoprostanes: Are They More Than Physiopathological Biomarkers of Lipid Peroxidation? * Response
Circulation, June 24, 2003; 107 (24): e222 - e222.
[Full Text] [PDF]